Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2

International Journal of Hyperthermia

Volumn 25, Issue 2, 2009, Pages 132-140

  Bevanda, Milenko ^a   Orsolic, Nada ^b   Basic, Ivan ^b   Vukojevic, Katarina ^c   Benkovic, Vesna ^b   Horvat Knezevic, Anica ^b   Lisicic, Duje ^b   Dikic, Domagoj ^b   Kujundzic, Milan ^d  

^a Clinical Hospital Mostar   (Bosnia and Herzegovina)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF SPLIT   (Croatia)

^d University of Zagreb School of Medicine   (Croatia)

Author keywords

Chemotherapy; Hyperthermia; Interleukin 2; Mouse; Peritoneal carcinomatosis

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; INTERLEUKIN 2; MITOMYCIN; MUTOMYCIN; PLATIMID; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; FEMALE; HYPERTHERMAL INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PERITONEAL CAVITY; SURVIVAL TIME; ANIMAL; BODY TEMPERATURE; CANCER TRANSPLANTATION; CARCINOMA; CBA MOUSE; DISEASE MODEL; HUMAN; IMMUNOTHERAPY; METHODOLOGY; PERITONEUM TUMOR; REGIONAL PERFUSION; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY TEMPERATURE; CARCINOMA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67649641966     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730802520697     Document Type: Article

References (36)

1. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743.
2. Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Myers CE. Prospective randomized trial of intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 1985;12:101-111.
3. Lindegaard JC, Radacic M, Khalil AA, Horsman MR, Overgaard J. Cisplatin and hyperthermia treatment of a C3H mammary carcinoma in vivo. Importance of sequence, interval, drug dose, and temperature. Acta Oncol 1992;31:347-351.
4. Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 2006;66:5419-5426.
5. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: Synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975;72:937-940.
6. Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am 1989;27:621-627.
7. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cisdiamminedichloroplatinum( II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: Acomparison with systemic chemotherapy. Cancer Res 1989;49:3380-3384.
8. Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D, Smals O, Gonzalez-Gonzalez D, McVie JG. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991;27:472-477.
9. Basic I, Varga E. Immunogenicity of mammary carcinoma and a fibrosarcoma of CBA mice. Period Biol 1979; 81:335-337.
10. Oršolić N, Bašić I. Immunomodulation by water-soluble derivative of propolis (WSDP) a factor of antitumor reactivity. J Ethnopharmacol 2003;84:265-273.
11. Plowman J, Dykes DJ, Hollingshead M. Anticancer drug development guide: Preclinical screening, clinical trials, and approval. Totowa, NJ: Humana; 1995. p 101.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-465.
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
14. Farrar WL, Johnson HM, Farrar JJ. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol 1981;126:1120-1125.
15. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984;223:1412-1414.
16. Hadden JW. Recent advances in the preclinical and clinical immunopharmcology of interleukin-2: Emphasis on IL-2 as an immunorestorative agent. Cancer Detect Prev 1988; 12:537-552.
17. Oršolić N, Horvat Knežević A, S ̌ ver L, Terzić S, Bašić I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. J Ethnopharmacol 2004;94:307-315.
18. Ben Salah-Abbès J, Abbès S, Houas Z, Abdel-Wahhab MA, Oueslati R. Zearalenone induces immunotoxicity in mice: Possible protective effects of radish extract (Raphanus sativus). J Pharm Pharmacol 2008;60(6):761-770.
19. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Jezzi M, De Giovanni C, Lollini PL. Antimetastatic activity of a preventive cancer vaccine. Cancer Res 2007;67(22): 11037-11044, 12034.
20. Ehrke MJ. Immunomodulation in cancer therapeutics. Int Immunopharmacol 2003;3:1105-1119.
21. Sugarbaker PH. A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 2005;32: S68-73.
22. Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 1998;4:121-140.
23. Zylberberg B, Dormont D, Janklewicz S, Darai E, Bretel JJ, Poncelet C, Guillet JL, Madelenat P. Response to neoadjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol 2001;22:40-45.
24. de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002; 79:46-61.
25. Marmor JB. Interactions of hyperthermia and chemotherapy in animals. Cancer Res 1979;39:2269-2276.
26. Fu QG, Meng FD, Shen XD, Guo RX. Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. World J Gastroenterol 2002;8(6):1019-1022.
27. Comella P, Crucitta E, De Vita F, De Lucia L, Farris A, Del Gaizo F, Palmeri S, Lannelli A, Mancarella S, Tafuto S, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: Arandomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002;13:866-873.
28. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: Interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
29. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631-636.
30. Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin Oncol 1989;16:230-253.
31. Mihich E. Historical overview of biologic response modifiers. Cancer Invest 2000;18:456-466.
32. Newman RA, Dogramatzis D, Benvenuto JA, Trevino M, Stephens LC, Wondergem J, Strebel R, Baba H, Bull JM. Effect of whole-body hyperthermia on pharmacokinetics and tissue distribution of doxorubicin. Int J Hyperthermia 1992;8(1):79-85.
33. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA and protein synthesis in cell-free systems and intact cells. Cancer Research 1976;36:2891-2895.
34. Ehrke MJ, Verstovsek S, Zaleskis G, Ho RL, Ujhazy P, Maccubbin DL, Mihich E. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother 1996;42: 221-230.
35. Nomura E, Niki M, Fujii K, Shinohara H, Nishiguchi K, Sonoda T, Tanigawa N. Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 2001;4:75-82. (Pubitemid 32899610)
36. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001;27:65-73.